Therapeutics: P. falciparum P-type cation-transporter ATPase 4 (PfATP4)

Mouse and in vitro studies have identified a new ATPase inhibitor that could help treat malaria infections. Whole genome sequencing of mutant strains of the P. falciparum parasite resistant to the compound identified PfATP4 as its target. In infected red blood cells, treatment with the ATPase4 inhibitor fully arrested parasite growth compared with no treatment. In a mouse model of malaria infection, treatment with the compound induced faster clearance of the parasite compared with artesunate or atovaquone. Next steps could include drug optimization studies and a clinical trial.

Sanofi markets ASAQ artesunate/amodiaquine, a fixed-dose combination of artesunate and amodiaquine, to treat malaria infection...